Mümtaz M Mazicioglu (Mumtaz Mazicioglu)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

High Performance Liquid Chromatography

Respiratory Syndrome Coronavirus

Top Venues

Pharmacology research & perspectives

This page only lists publications with an associated author ORCID identifier.

Publications

Ahmet Inal, Zafer Sezer, Berna Uluözlü, Melih Oflas, Martin Reinsch, Wolfgang Martin, Mümtaz M Mazicioglu, Selma Alime Koru
Bioequivalence study of low dose drospirenone/ethinyl estradiol 3 mg/0.03 mg film tablets under fasting conditions in Turkish healthy female subjects. Pharmacology research & perspectives 12 (4) (2024)
Ahmet Inal, Zafer Sezer, Berna Uluözlü, Melih Oflas, Martin Reinsch, Wolfgang Martin, Mümtaz M Mazicioglu, Selma Alime Koru
Bioequivalence study of low dose drospirenone/ethinyl estradiol 3 mg/0.03 mg film tablets under fasting conditions in Turkish healthy female subjects. Pharmacology research & perspectives 12 (4) (2024)
Zafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, Hazel Yetiskin, Büşra Kaplan, Muhammet Ali Uygut, Ahmet Furkan Aslan, Adnan Bayram, Mümtaz M Mazicioglu, Gamze Kalin Unuvar, Zeynep Ture Yuce, Gunsu Aydin, Refika Kamuran Kaya, Ihsan Ates, Ateş Kara, Aykut Ozdarendeli
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines 12 (2) (2024)
Zafer Sezer, Shaikh Terkis Islam Pavel, Ahmet Inal, Hazel Yetiskin, Büşra Kaplan, Muhammet Ali Uygut, Ahmet Furkan Aslan, Adnan Bayram, Mümtaz M Mazicioglu, Gamze Kalin Unuvar, Zeynep Ture Yuce, Gunsu Aydin, Refika Kamuran Kaya, Ihsan Ates, Ateş Kara, Aykut Ozdarendeli
Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up. Vaccines 12 (2) (2024)